Narrative review / 2021
Approved anti-obesity drugs combined with lifestyle interventions show 12-month placebo-subtracted weight reductions ranging from 2.9% to 6.8%.
This review evaluates the long-term efficacy and safety of medical treatments for obesity alongside lifestyle interventions. Recent meta-analyses indicate that 12-month placebo-subtracted weight reduction ranges from 2.9% to 6.8% across various agents: phentermine/topiramate (6.8%), liraglutide (5.4%), naltrexone/bupropion (4.0%), orlistat (2.9%), and lorcaserin (3.1%). Lorcaserin was withdrawn by the FDA in February 2020 due to an increased risk of cancer observed in a clinical trial. Currently approved drugs for chronic management (orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide) can be costly and have adverse effects, requiring individualized benefit-risk assessment.
- Study type
- Narrative review
- Who was studied
- Patients with obesity or who are overweight
- What was measured
- Weight reduction and safety of anti-obesity drugs
THE PAPER
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ, Lee SY. Curr Obes Rep, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.